Literature DB >> 14596917

The ubiquitin-protein ligase activity of Hdm2 is inhibited by nucleic acids.

Laëtitia K Linares1, Martin Scheffner.   

Abstract

The proto-oncoprotein Hdm2 is a member of the RING finger-type family of ubiquitin-protein ligases E3. The RING finger domain is assumed to mediate the specific interaction of an E3 with its cognate ubiquitin-conjugating enzyme E2, which catalyzes the covalent attachment of ubiquitin to substrate proteins. In addition, the RING finger domain of Hdm2 is involved in Hdm2 homooligomer formation and has the capacity to bind to RNA in a sequence-specific manner. Here we report that interaction with nucleic acids interferes with both Hdm2/Hdm2 complex formation and auto-ubiquitination of Hdm2 in vitro. Furthermore, although binding of Hdm2 to the tumor suppressor p53 is not inhibited by nucleic acids, Hdm2-mediated ubiquitination of p53 is significantly decreased. Taken together, these results provide the first example of an E3 whose activity can be regulated by direct interaction with nucleic acids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14596917     DOI: 10.1016/s0014-5793(03)01108-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Casein kinase 1α regulates an MDMX intramolecular interaction to stimulate p53 binding.

Authors:  Shaofang Wu; Lihong Chen; Andreas Becker; Ernst Schonbrunn; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2012-10-01       Impact factor: 4.272

2.  Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo.

Authors:  Harumi Shimizu; David Saliba; Maura Wallace; Lee Finlan; Patrick R R Langridge-Smith; Ted R Hupp
Journal:  Biochem J       Date:  2006-07-15       Impact factor: 3.857

3.  beta-arrestin 2 oligomerization controls the Mdm2-dependent inhibition of p53.

Authors:  Cédric Boularan; Mark G H Scott; Karima Bourougaa; Myriam Bellal; Emmanuel Esteve; Alain Thuret; Alexandre Benmerah; Marc Tramier; Maité Coppey-Moisan; Catherine Labbé-Jullié; Robin Fåhraeus; Stefano Marullo
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-05       Impact factor: 11.205

4.  Discovery of N-(3,4-Dimethylphenyl)-4-(4-isobutyrylphenyl)-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinoline-8-sulfonamide as a Potent Dual MDM2/XIAP Inhibitor.

Authors:  Zhongzhi Wu; Lubing Gu; Sicheng Zhang; Tao Liu; Pradeep B Lukka; Bernd Meibohm; John C Bollinger; Muxiang Zhou; Wei Li
Journal:  J Med Chem       Date:  2021-02-08       Impact factor: 8.039

5.  Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival.

Authors:  Tao Liu; Hailong Zhang; Jing Xiong; Sha Yi; Lubing Gu; Muxiang Zhou
Journal:  Mol Cancer       Date:  2015-03-26       Impact factor: 27.401

6.  Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.

Authors:  Jing Xiong; Jiansha Li; Qin Yang; Jun Wang; Tiefen Su; Sheng Zhou
Journal:  Breast Cancer Res       Date:  2017-03-09       Impact factor: 6.466

7.  Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.

Authors:  Katherine Heminger; Michael Markey; Meldrick Mpagi; Steven J Berberich
Journal:  Aging (Albany NY)       Date:  2009-01       Impact factor: 5.682

8.  FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2.

Authors:  T Liu; J Xiong; S Yi; H Zhang; S Zhou; L Gu; M Zhou
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.